Portfolio Companies News
April 25, 2017Wilson Therapeutics presents promis...
Apr 25, 2017 Wilson Therapeutics AB (publ), announced today a poster presentation at the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, MA, 22-28 April, 2017, highlighting the results on neurological parameters from the recently completed Phase 2 trial of WTX101 (bis-choline t... read more
April 25, 2017Targovax ASA: First quarter 2017 re...
Oslo, Norway, 25 April 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2017 results. A meeting for investors, analysts and press will take place in Osl... read more
April 24, 2017Aarhus University Hospital in Denma...
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that Aarhus University Hospital, Denmark has recently purchased a... read more
April 24, 2017Wilson Therapeutics presented posit...
Wilson Therapeutics AB (publ), announced today that the final data from the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, were presented a... read more
April 24, 2017Clinigen and Onxeo initiate Managed...
Paris, April 24, 2017 – 18:30 CEST. Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Onxeo S.A (Euronext Paris, Nasdaq Copenhagen: ONXEO, ‘Onxeo’), have agreed to launch a Managed Access programme for belinostat (Beleodaq®) in Europe.... read more
February 06, 2017Q4 2016 General Market Overview
- 106 Since the start in 1996, HealthCap funds have invested in 106 portfolio companies.
- 39 39 of the portfolio companies have been taken public on nine different markets.
- 22 22 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 6 companies with a valuation of USD 1 billion or more and 34 companies with a valuation of SEK 1 billion or more.